Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.70 |
| ▸ | HTR2A | P28223 | 5/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051426 | 0.91 | TAAR1 (0.61) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL6314758 | 0.91 | HTR2A (0.74) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL6638715 | 0.87 | TAAR1 (0.56) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL2907330 | 0.87 | TAAR1 (0.60) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL10862161 | 0.87 | TAAR1 (0.67) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL6875195 | 0.87 | TAAR1 (0.60) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL3057797 | 0.87 | TAAR1 (0.60) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL10414028 | 0.87 | TAAR1 (0.62) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL18653966 | 0.87 | TAAR1 (0.60) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL28597876 | 0.87 | TAAR1 (0.56) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4107223-A1 | LOW DENSITY FLAME RETARDANT TWO-COMPONENT COMPOSITION FOR STRUCTURAL VOID FILLING | Zephyros Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| US-9862798-B2 | Epoxy liquid curing agent compositions | EVONIK DEGUSSA GMBH (DE) | 2018-01-09 | — | — | US | claimed |
| EP-3052541-A1 | EPOXY LIQUID CURING AGENT COMPOSITIONS | Air Products and Chemicals, Inc. (US) | 2016-08-10 | — | — | EP | claimed |
| US-20150094400-A1 | Epoxy Liquid Curing Agent Compositions | AIR PRODUCTS AND CHEMICALS INC. (US) | 2015-04-02 | — | — | US | claimed |
| WO-2015048701-A1 | EPOXY LIQUID CURING AGENT COMPOSITIONS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2015-04-02 | — | — | WO | claimed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | claimed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | claimed |
| JP-4460292-B2 | — | — | 2010-05-12 | — | — | JP | claimed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | claimed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | claimed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | claimed |
| WO-2003032997-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | claimed |
| EP-0955318-A1 | Gels derived from extending grafted alpha-olefin-maleimide centipede polymers and polypropylene | Bridgestone Corporation (JP) | 1999-11-10 | — | — | EP | claimed |
| EP-0955316-A1 | Gels derived from extending grafted centipede polymers and polypropylene | Bridgestone Corporation (JP) | 1999-11-10 | — | — | EP | claimed |
| EP-0955319-A1 | Soft compounds derived from polypropylene grafted disubstituted ethylene-maleimide copolymers | Bridgestone Corporation (JP) | 1999-11-10 | — | — | EP | claimed |
| EP-0955317-A1 | Grafted maleimide-styrene-g-polypropylene copolymers used in rubber compounds for increasing hysteresis | Bridgestone Corporation (JP) | 1999-11-10 | — | — | EP | claimed |
| EP-0879832-A1 | High damping gel derived from extending grafted elastomers and polypropylene | Bridgestone Corporation (JP) | 1998-11-25 | — | — | EP | claimed |
| EP-0879831-A1 | An extended polymer composition derived from grafted elastomers and polypropylene | Bridgestone Corporation (JP) | 1998-11-25 | — | — | EP | claimed |
| US-5646209-A | Thermoplastic resin composition comprising liquid crystalline polyester, aromatic polycarbonate and glass fiber | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-07-08 | — | — | US | claimed |
| EP-0441545-A1 | Two-component curable hot-melt resin compositions | Union Camp Corporation (US) | 1991-08-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | TAAR1 498/4885HTR2A 3506/4885CYP2A6 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.